Several biomarkers of venetoclax response in AML have been proposed at the protein [BCL-XL, MCL-1, and BCL-233] and mRNA [BCL2, BCL2/MCL1 ratio, BCL2A1, CD11b, CD14, CD68, CD86, CLEC7A (CD369), HOX gene family members, MCL1, S100A8, and S100A99,34–37] levels. This evidence concerns the gene CD14 and acute myeloid leukemia.